novo nordisk semaglutide mash Management and Information semaglutide novo nordisk Novo Nordisk

Doctors report that GLP-1 medications, originally approved for obesity and diabetes, are increasingly being used to help women with Polycystic Ovary Syndrome (PCOS) a hormonal disorder often tied to weight gain, insulin resistance, and fertility issues

Results from the OUTSTAND-1 trial showed Hengrui/Kailera's HRS-7535 (KAI-7535) cut HbA1c by a highest placebo-adjusted 1.62% at 32 weeks, based on the treatment efficacy estimand.

DEXA body composition tracking included.

Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)